問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Chi Mei Hospital, Liouying (在職)

Division of Obstetrics & Gynecology

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Urology

Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Chi Mei Medical Center

更新時間：2023-09-19

黃文聰
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

109Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃文聰

Chi Mei Hospital, Liouying

Division of Hematology & Oncology

List

137Cases

2009-07-01 - 2011-06-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2009-07-01 - 2011-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2011-09-01 - 2013-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2020-11-01 - 2022-03-11

Phase II

A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor–Naïve With Selected Solid Tumors

  • Condition/Disease

    Non Small Cell Lung Cancer / Urothelial Cancer / Renal Cell Carcinoma / Hepatocellular Carcinoma / Melanoma

  • Test Drug

    INCB086550

Participate Sites
7Sites

Recruiting3Sites

Terminated4Sites

2019-06-01 - 2021-09-28

Phase II

A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    M7824

Participate Sites
5Sites

Recruiting5Sites

2020-05-01 - 2023-01-31

Others

A two-stage, multi-center, open-label, randomized, controlled trial comparing the efficacy and safety of intra-peritoneal infusion of catumaxomab and treatment of investigator choice in patients with advanced gastric carcinoma with peritoneal metastasis

  • Condition/Disease

    advanced gastric carcinoma with peritoneal metastasis

  • Test Drug

    Catumaxomab

Participate Sites
4Sites

Recruiting4Sites

2009-01-01 - 2011-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2008-10-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2009-10-01 - 2014-10-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2016-02-15 - 2019-12-31

Phase II

A single-arm, open-label, Phase 2 study evaluating the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    HM61713

Participate Sites
6Sites

Terminated6Sites

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

1 10 11 12 13 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB